INSIGHTS ON CLINICAL TRIAL PARTNERING

• The Path Forward In Oncology Trials

  A comprehensive site support model is crucial for navigating the complexities of modern oncology trials and accelerating drug development.

• Flexible Packaging, Labeling And Distribution For Diverse Drug Types

  Learn how demand-led and hybrid clinical supply models reduce waste, accelerate timelines, and improve flexibility for global trials through regional hubs and patient-specific packaging strategies.

• Reframing Vendor Selection: Beyond Price And Past Relationships

  An RFP is more than a budget tool — it’s a strategic communication document that guides vendors, clarifies expectations, and enables informed, data-driven sponsor decisions.

• How Do Site Payments Impact Clinical Trial Sustainability?

  Financial stability is critical for trial sites, yet many sites grapple with substantial payment delays. To mitigate these challenges, it's imperative to reassess traditional payment practices,

• Enhancing Phase 1 Clinical Trials With Point-Of-Need Safety Assessments

  2/3/2025

  A Mobile Clinical Suite (MCS) proved to be the solution that Syneos Health needed to resolve their Phase 1 study trial challenges with comprehensive eye exams.

• The Lasting Impact Of Treatment Gaps In ARG1-D

  6/26/2026

  A patient story from ARG1-D reveals how even brief treatment interruptions can trigger irreversible decline and why continuity of care must remain a priority in rare disease research.

• Building Bioanalysis Infrastructure For Modern Drug Development

  10/20/2025

  Drug development accelerates with AI, decentralized trials, and adaptive protocols, but legacy CRO infrastructure lags. Platform-based systems enable speed, quality, automation, and continuous improvement.

• Delivering Successful Cell And Gene Therapy Trials

  9/10/2025

  Successfully executing complex cell and gene therapy trials hinges on meticulous operational strategies and a patient-centric approach.

• What Sponsors Get Wrong When Selecting A CRO

  3/9/2026

  Gene therapy immunogenicity requires platforms, judgment, and regulatory fluency beyond ADA norms. Relying on biologics criteria creates gaps; CGT expertise ensures reliable, interpretable results.